ORGO Earnings Prediction
The chart below shows how ORGO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ORGO sees a +7.32% change in stock price 10 days leading up to the earnings, and a -2.90% change 10 days following the report. On the earnings day itself, the stock moves by -2.44%. This data can give you a slight idea of what to expect for the next quarter's release.
ORGO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
115.18M
6.12%
-11.56%
Gross Margin
76.73%
0.64%
-1.10%
Operating Margin
5.42%
-39.64%
-20.76%
Net Margin
10.71%
266.78%
-181.82%
EPS
0.09
350.00%
-169.23%
No Data Available
ORGO Earnings Analysis
Organogenesis Holdings Inc. Class A Common Stock Corporation (ORGO.O) Earnings Conference Call
Positive
Third Quarter Net Revenue: Net revenue for the third quarter was $115.2 million, up 6%.
Wound Care Revenue Increase: Advanced wound care net revenue for the third quarter was $108 million, up 7%.
Gross Profit Margin Increase: Gross profit for the third quarter was $88 million, or 76.7% of net revenue compared to 76.2% last year.
Quarterly Adjusted Net Income: Adjusted net income for the third quarter was $12.9 million compared to $5.3 million last year.
Cash and Cash Equivalents: The company had $94.9 million in cash, cash equivalents and restricted cash as of September 30, 2024.
Negative
Net Income Decline: Net income for the third quarter was $12.3 million compared to net income of $13.2 million last year, a decrease of $0.9 million or 6.8%.
Operating Income Decline: Operating income for the third quarter was $6.2 million compared to operating income of $8.1 million last year, a decrease of $1.8 million or 22%.
Operating Expenses Increase: Operating expenses for the third quarter were $82.1 million compared to $74.7 million last year, an increase of $7.4 million or 10%.
EBITDA Decline Analysis: Adjusted EBITDA for the third quarter was $13.4 million, or 12% of net revenue compared to $16 million, or 14.7% of net revenue last year, reflecting a decline in profitability.
R&D Expense Decline: Research and development expenses declined 1% year-over-year but decreased 34% sequentially, indicating a significant drop in investment in this area.
ORGO FAQs
How does ORGO typically perform around its earnings report dates?
Is Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ORGO Earning Call Sentiment
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ORGO.O
-1.43%Positive
The earnings call presents mixed signals. Financial performance shows revenue growth but decreased operating income, indicating pressure. Positive factors include improved guidance and strategic growth initiatives funded by a private placement. However, unclear responses in the Q&A and increased operating expenses pose concerns. Overall, these factors balance out, leading to a neutral sentiment prediction for the stock price.